Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
Workforce Reduction: Pliant Therapeutics is implementing a strategic restructuring that includes a 45% reduction in its workforce to extend cash reserves for late-stage clinical trials, particularly the BEACON-IPF trial.
Upcoming Data Release: The company expects to release topline data from the BEACON-IPF trial in the second quarter of 2025, which will inform future steps in the development of their lead product candidate, bexotegrast.
Get Free Real-Time Notifications for Any Stock
Analyst Views on PLRX
About PLRX
About the author

Combination of Pliant Cancer Drug and Merck's Keytruda Enhances Treatment Responses in Challenging Tumors
Pliant Therapeutics' Trial Results: Pliant Therapeutics released promising interim data from its Phase 1 trial of PLN-101095, showing antitumor activity in combination with Merck's Keytruda in patients with advanced solid tumors that are refractory to immune checkpoint inhibitors.
Clinical Responses Observed: Among the heavily pretreated patient population, there were four responders, including one complete response and three partial responses, with clinical responses noted in various cancer types such as cholangiocarcinoma and melanoma.
IFN-γ Levels and Tolerability: Responding patients exhibited significant increases in plasma interferon gamma levels, while PLN-101095 was generally well tolerated, demonstrating a dose-dependent pharmacokinetic profile.
Stock Performance and Future Plans: Despite the positive trial results, Pliant's stock fell by over 20%, trading near its 52-week low, while the company plans to initiate a Phase 1b trial in 2026 to further explore PLN-101095's efficacy in non-small cell lung cancer and other tumor types.

JP Morgan Lowers Pliant Therapeutics Rating to Underweight
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to help them make informed decisions in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.









